Home > Drugs A – Z > Fluticasone (Into the nose)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Fluticasone (Into the nose)

Treats allergy symptoms, such as itchy, runny, or stuffy nose. This is a steroid medicine.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Fluticasone nasal spray is used to treat sneezing, itchy or runny nose, or other symptoms caused by hay fever. This is a steroid medicine. This medicine is available only with your doctor's prescription… Read more
Brand names include
Flonase, Novaplus Fluticasone Propionate, Veramyst
Other forms
By breathing, On the skin
Drug classes About this
Corticosteroid, Intermediate, Corticosteroid, Strong
Combinations including this drug

What works? Research summarized

Evidence reviews

Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis

Bibliographic details: Masoli M, Weatherall M, Holt S, Shirtcliffe P, Beasley R.  Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. European Respiratory Journal 2006; 28(5): 960-967

The effectiveness and safety of ciclesonide versus fluticasone, budesonide, and beclomethasone in treatment of persistent asthma: a comprehensive review of literature

Bibliographic details: Zali Z, Akbari-Sari A, Yazdizadeh B, Hosseini A, Tabatabaei SA.  The effectiveness and safety of ciclesonide versus fluticasone, budesonide, and beclomethasone in treatment of persistent asthma: a comprehensive review of literature. Journal of Isfahan Medical School 2014; 32(278): 342-358 Available from: http://www.jims.mui.ac.ir/index.php/jims/article/view/2847/6186

Fluticasone and beclometasone: what are their effects on children's growth

Fear of growth retardation may account for the underuse of inhaled corticosteroids in children with asthma, despite compelling evidence of their effectiveness. This fear may be reduced with newer agents with lower oral bioavailability if their theoretical advantage of fewer systemic adverse effects than the standard treatment of inhaled beclometasone is realized in practice. This review aims to determine if one of the newer agents, inhaled fluticasone, has less effect on the growth of pre-pubertal asthmatic children than inhaled beclometasone. The outcome measure was growth velocity. Two double blind, randomized controlled trials were identified. In one of the studies the mean growth velocity in the fluticasone group was 0.7 cm/year greater than in the beclometasone group. In the second, smaller study the mean growth velocity in the fluticasone group was 0.8 cm/year greater. There is therefore some evidence that fluticasone has less (if any) adverse effect on growth.

See all (84)

Summaries for consumers

Fluticasone versus placebo for chronic asthma in adults and children

Fluticasone is a well‐established inhaled steroid for use a preventative agent in controlling asthma symptoms. This review found that it is highly effective even in low doses. The effect does appear to increase with higher doses, but these improvements are small. This drug is associated with symptoms such a thrush, sore throat and hoarseness and these get worse with higher doses. In people with severe asthma who need oral steroid tablets to control their asthma, it can reduce the dose of oral steroids they need and improve their asthma at the same time. However, high or very high doses are needed for this effect. The drug appears to work in children and adults.

Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children

This review compares the effectiveness of three inhaled steroids. Fluticasone (FP) was compared with either beclomethasone (BDP) or budesonide (BUD) for treating people with chronic asthma. When FP was given to children or adults at approximately half the daily dose of either BDP or BUD, it appeared to be at least as effective as the other two drugs in improving airway opening. There was not enough information available to draw conclusions concerning the effect of these drugs on symptoms, or the risk of an acute asthma exacerbation. When given at the same dose as BDP or BUD, FP treated participants had slightly better lung function. However, at the same dose FP was also associated with increased hoarseness, although it did not lead to increased incidences of other side‐effects associated with steroids such as oral thrush or sore throat.

Inhaled fluticasone versus 'extrafine' HFA‐beclomethasone dipropionate for chronic asthma in adults and children

Inhaler devices used to deliver steroids in asthma broadly fall into three categories. Those which use a propellant to dispense the steroid in to the airway via the mouth when the canister is pressed manually (pressurised metered dose inhalers ‐ pMDIs), those which use a propellant to deliver a dose of the steroid triggered by the user breathing in (breath actuated MDIs), and those which deliver the drug as dry powder (DPI). The pMDIs have traditionally used a chlorofluorocarbon (CFC) propellant, but the phasing out of CFC‐inhalers has had major implications for the manufacturing of inhaled drugs. A new non‐CFC propellant (hydrofluoroalkane‐134a (HFA)) has been introduced, and it is used to propel beclomethasone (BDP). Previously fluticasone (FP) was thought to be at least as effective as CFC‐BDP when given at half the dose. The review of studies found that there was a limited amount of evidence to show that the newer extra‐fine form of BDP was similar to FP at the same dose. More research should be done in children and in people with more severe asthma to help answer the question of what the relative effects of these two steroids are. Some people may not be particularly good at using certain inhaler types and the findings of the review may only really apply to people who are competent in using metered‐dose inhalers (MDIs). Studies should consider introducing spacers where people find these easier to use.

See all (34)

PubMed Health Blog...

read all...